(Total Views: 334)
Posted On: 09/25/2018 10:07:27 AM
Post# of 72447
I have appealed the removal of this post I made this morning at IHUB.
Post Date: 9/25/2018 8:41:03 AM in reply to 143768912 by georgejjl
Board: Innovation Pharmaceuticals Inc. Reason: Off-Topic
George: Thanks for your continuing P posts. I smiled yesterday remembering your belief that P could be a 10-15 billion dollar drug. I thought of that as I read this CITI anylist's comment about AMRN which opened yesterday @ $2.99 and closed at $12.40.
Citi sees another 5x upside in Amarin
Sep. 24, 2018 11:53 AM ET|By: Stephen Alpher, SA News Editor
Amarin (NASDAQ:AMRN) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.
Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: Notable Calls
Also on the move on the news is Acasti Pharma (ACST +26.9%), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.
Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)
If they are worth $50.00 in a buyout with a single drug just imagine what we will be worth with multiple blockbusters! Just goes to show how undervalued we are at this time. Go IPIX!!!
Post Date: 9/25/2018 8:41:03 AM in reply to 143768912 by georgejjl
Board: Innovation Pharmaceuticals Inc. Reason: Off-Topic
George: Thanks for your continuing P posts. I smiled yesterday remembering your belief that P could be a 10-15 billion dollar drug. I thought of that as I read this CITI anylist's comment about AMRN which opened yesterday @ $2.99 and closed at $12.40.
Citi sees another 5x upside in Amarin
Sep. 24, 2018 11:53 AM ET|By: Stephen Alpher, SA News Editor
Amarin (NASDAQ:AMRN) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.
Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: Notable Calls
Also on the move on the news is Acasti Pharma (ACST +26.9%), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.
Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)
If they are worth $50.00 in a buyout with a single drug just imagine what we will be worth with multiple blockbusters! Just goes to show how undervalued we are at this time. Go IPIX!!!
(5)
(0)
